NeuroSigma Announces Acceptance into 2024 Cohort of the KidsX Accelerator Program
May 09, 2024 09:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. today announced its acceptance into the 2024 cohort of the KidsX Accelerator Program. KidsX is a global leader in pediatric digital...
NeuroSigma Announces FDA Clearance of its Second-Generation Monarch eTNS System for Treating Pediatric ADHD
January 18, 2024 00:21 ET
|
NeuroSigma, Inc.
LOS ANGELES, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NeuroSigma today announced that the U.S. Food and Drug Administration (FDA) cleared use of NeuroSigma’s second-generation Monarch eTNS System for...
NeuroSigma Announces FDA 510(k) Submission for Second Generation Monarch eTNS System
November 07, 2023 08:50 ET
|
NeuroSigma, Inc.
LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its second-generation...